Long-term lanreotide treatment in six patients with congenital hyperinsulinism

What Was Tested

Researchers studied Somatostatin and Lanreotide in this clinical trial publication.

However, only few drugs are available and even fewer are approved as a medical therapy to maintain normal blood glucose levels.

The established therapies are demanding for caregivers and complicated by different side effects such as gastrointestinal symptoms, hypertrichosis, and obesity.

Who Took Part

The abstract describes 6 patients taking part.

By PubMed's age tags, the people studied were infants and young children, both men and women.

The researchers report the use of the very-long-acting somatostatin analogue lanreotide autogel in 6 patients with CHI over a mean duration of 40.8 months.

What Was Measured

However, only few drugs are available and even fewer are approved as a medical therapy to maintain normal blood glucose levels.

The established therapies are demanding for caregivers and complicated by different side effects such as gastrointestinal symptoms, hypertrichosis, and obesity.

Topics PubMed links to this paper include Antineoplastic Agents, Blood Glucose, Congenital Hyperinsulinism, Peptides, Cyclic and Somatostatin.

What This Means in Plain Language

This is a clinical trial of Somatostatin and Lanreotide in 6 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.